基础医学与临床 ›› 2015, Vol. 35 ›› Issue (6): 846-850.

• 短篇综述 • 上一篇    下一篇

垂体生长激素腺瘤对生长抑素类似物的耐药机制研究进展

李一琳1,郭晓鹏1,幸兵2   

  1. 1. 北京协和医学院
    2. 北京协和医院
  • 收稿日期:2015-01-09 修回日期:2015-03-21 出版日期:2015-06-05 发布日期:2015-05-27
  • 通讯作者: 幸兵 E-mail:xingbingemail@aliyun.com

Research progress on mechanisms of resistance to somatostatin analogs in growth hormone-secreting pituitary adenomas

Yi-Lin LI1, 1,Bing XING   

  • Received:2015-01-09 Revised:2015-03-21 Online:2015-06-05 Published:2015-05-27
  • Contact: Bing XING E-mail:xingbingemail@aliyun.com

摘要: 生长抑素类似物能抑制垂体生长激素细胞对生长激素的分泌及相关肿瘤细胞的增殖,是目前垂体生长激素腺瘤临床治疗的首选药物。但部分患者因耐药而影响疗效,其耐药机制涉及生长抑素受体、受体下游信号传导通路、组织病理和细胞黏附分子等因素。

关键词: 垂体生长激素腺瘤, 肢端肥大症, 生长抑素类似物, 耐药

Abstract: Somatostatin analogs are the mainstay of medical therapy for growth hormone-secreting pituitary adenomas. They can inhibit the growth hormone secretion in pituitary gland and the proliferation of tumor cells. However, some patients get unsatisfying curative effect because of drug resistance. The mechanisms of somatostatin analog resistance mainly are related to somatostatin receptor, downstream signaling pathways, histopathology, adhesion molecule and other factors.

Key words: growth hormone-secreting pituitary adenomas, acromegaly, somatostatin analog, resistance

中图分类号: